Writing & StyleStyle guide

Randomization Scheme in Clinical Study Report

ICH E3 appendix 16.1.7 identifies the randomization scheme and codes as study-information material supporting the clinical study report. This appendix is relevant only when randomization was used and should not be generalized into a requirement for nonrandomized studies.

Quick answer

The Randomization Scheme appendix provides the allocation scheme and codes needed to understand or verify treatment assignment in a randomized study.

Key details

Core IssueICH E3 appendix 16.1.7 identifies the randomization scheme and codes as study-information material supporting the clinical study report.
Registerscholarly, professional, or research/report writing

Important caveats

Scope Boundary

This appendix is relevant only when randomization was used and should not be generalized into a requirement for nonrandomized studies.

Further guidance

Content

Place the randomization scheme and relevant codes in the designated appendix and keep their interpretation consistent with the randomization methods described in the report body.

Purpose

The Randomization Scheme appendix provides the allocation scheme and codes needed to understand or verify treatment assignment in a randomized study.

Sources and evidence

Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.

  1. E3 Structure and Content of Clinical Study Reports (opens in a new tab)U.S. Food and Drug Administration · FDA-hosted ICH E3 guidance defining the structure and content of a core clinical study report

Related guides

Writing & Style

Abnormal Laboratory Value Listing in Clinical Study Report

ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.

Writing & Style

Active-Control Studies Intended to Show Equivalence in Clinical Study Report

ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.

Writing & Style

Adjustments for Covariates in Clinical Study Report

ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.

Writing & Style

Adverse Event Listings in Clinical Study Report

ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.

Writing & Style

Analysis of Adverse Events in Clinical Study Report

ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.

Writing & Style

Analysis Population Identification in Clinical Study Report Displays

ICH E3 emphasizes that analyses, tables, and figures should clearly identify the set of patients from which the displayed result was generated. This is a results-display identification rule, not a substitute for prospectively defining analysis populations in a protocol or statistical analysis plan.

Writing & Style

Appropriateness of Measurements in Clinical Study Report

ICH E3 section 9.5.2 calls for discussion of the appropriateness, reliability, or relevance of measurements used to assess efficacy and safety when explanation is needed. This subsection justifies or qualifies measurement choices; it does not replace the section that defines the variables, methods, and timing of assessments.

Explore the topic